Canada's Voice For
Biotechnology
Members
| Location: |
Toronto, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.marsdd.com |
| Contact: |
Ilse Treurnicht (marsdiscoverydistrict@marsdd.com)
1 416 6738100
|
| Description: |
MaRS is a non-profit innovation centre connecting science, technology and social entrepreneurs with business skills, networks and capital to stimulate innovation and accelerate the creation and growth of successful Canadian enterprises. |
| Location: |
Winnipeg, Manitoba |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.marsalabiotech.com/ |
| Contact: |
George Thomas (info@marsalabiotech.com)
1 204 9287904
|
| Description: |
Marsala Biotech is a drug development company concentrating on new treatments for cancer, with a primary focus on two products: Through a joint venture relationship with Guangzhou Doublle Bioproducts Inc, Marsala has acquired E10A, an investigational gene therapy that utilizes an adenovector to deliver the endostatin gene. E10A has successfully completed a Phase-II trial in June 2011 and a Phase III trial for head and neck cancer, would be initiated by mid 2013. An in-house drug discovery program to develop new chemical entities (NCEs) for the treatment/management of cancer. Both of these technologies have the potential to treat a wide variety of cancers. E10A is selective in that it targets a tumor's acute need for new blood vessel creation. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.marsh.ca |
| Contact: |
Suzanne Liberman (suzanne.a.liberman@marsh.com)
1 416 349-4381
|
| Description: |
Marsh is a leading broker and risk advisor. Company provides advice and transactional capabilities to clients in over 100 countries. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.mccarthy.ca |
| Contact: |
Carol Hastie (chastie@mccarthy.ca)
1 604 6437100
|
| Description: |
McCarthy Tétrault provides a broad range of legal services, advising on large and complex assignments for Canadian and international interests. The firm has substantial presence in Canada’s major commercial centres and in London, UK. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.medec.org |
| Contact: |
Barbara Leavitt (medec@medec.org)
1 416 620 1915
|
| Description: |
MEDEC is the national association created by and for the Canadian medical device industry. MEDEC is the primary source for advocacy, information and education on the medical device industry for members, the greater healthcare community, industry partners and the general public. |
| Location: |
Victoria, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.med-genesis.com/ |
| Contact: |
Michael Lincoln (info@MedGenesis.com)
1 250 3863000
|
| Description: |
MedGenesis Therapeutix Inc. is a specialty biopharmaceutical company with a focus on targeted medicines, in particular glial cell line-derived neurotrophic factor (GDNF) protein, leveraging targeted delivery techniques such as convection enhanced delivery (CED) to develop and commercialize innovative treatments for patients with serious central nervous system (CNS) diseases. |
| Location: |
Québec, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.medicago.com |
| Contact: |
Andrew J. Sheldon (info@medicago.com)
1 418 6589393
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): MDG.TO |
| Description: |
Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary VLP and manufacturing technologies. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Contact: |
Fahar Merchant (fmerchant@medicenna.com)
|
| Description: |
Medicenna is focused on developing a new generation of receptor targeted therapeutic fusion proteins (Fuzin™) designed to specifically deliver potent pro- or anti-apoptotic payloads for the treatment of cancer, and degenerative diseases, respectively. Medicenna’s novel platform will be strategically deployed to build a pipeline of differentiated Fuzin™ candidates consisting of a validated targeting domain and a potent payload fused via a proprietary linker. |
| Location: |
Winnipeg, Manitoba |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.medicure.com/ |
| Contact: |
Dawson J. Reimer (dreimer@medicure.com)
1 204 4877412
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): MPH-H.V |
| Description: |
Medicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company’s vision is to become a leading specialty pharmaceutical company in the commercialization and development of unique small molecule pharmaceuticals in the cardiovascular and neurological fields for unmet medical needs. |
| Location: |
Québec, Quebec |
| Industry Sector: |
Pharma |
| Website: |
www.medunikcanada.com/ |
| Contact: |
Louis-Jules Dagenais (ljdagenais@medunikcanada.com)
1 450 433-4441
|
| Ownership: |
Subsidiary - : |
| Description: |
Médunik Canada is an addition to Le Groupe Pharmaceutique Boivin, a Canadian family-owned organization based in the greater Montréal area since 1955. The compan's focus is to improve the health and quality of life of Canadians with rare diseases. Médunik Canada’s mission is to bring to Canada currently unavailable orphan drugs for women, men and children with rare diseases. Through in-licensing partnerships, Médunik Canada is offering turn-key operations, including the approval process and commercialization of these novel treatments. |
| Location: |
Edmonton, Alberta |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.biomsmedical.com |
| Contact: |
Tony Hesby (thesby@medwellcapital.com)
1 780 413 7152
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): MWC |
| Description: |
Medwell Capital Corp. is a Canadian-based service provider of capital and advisory services for the healthcare industry. The Company is organized into three separate business units: Medwell Investments: Manages the $40 million assets under management. Medwell Consulting: Performs internal pharma-level diligence analysis in support of investments, and provides clinical, advisory, regulatory and consulting services to companies. Medwell Securities: Acquired a licensed Exempt Market Dealer and award winning healthcare investment banking team to provide strategic advisory, financing and M&A services. |
| Location: |
Kirkland, Quebec |
| Industry Sector: |
Pharma |
| Website: |
www.merckfrosst.ca/mfcl/en/corporate/index.html |
| Contact: |
Marlene Gauthier
1 514 428 8600
|
| Ownership: |
Subsidiary - : |
| Description: |
Merck Frosst of Merck & Co., Inc. is a Canada research-based pharmaceutical company. Merck Frosst is active in the treatment of asthma, osteoporosis, glaucoma, prostate disease, migraines and infectious diseases. The company also markets an extensive line of cardiovascular products for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines. |
| Location: |
Cambridge, Massachusetts |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.metabolix.com |
| Contact: |
Richard P. Eno (info@metabolix.com)
1 617 6824693
|
| Ownership: |
Public - NASDAQ: MBLX |
| Description: |
Metabolix, Inc. is a bioscience company focused on providing sustainable solutions for the world's need for plastics, chemicals and energy. They develop and commercializes PHA bioplastics, a sustainable and biodegradable alternative to petroleum based plastics. Metabolix is also developing a proprietary platform technology for co-producing plastics, chemicals and energy from crops. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.methylgene.com |
| Contact: |
Joseph Walewicz (bd@methylgene.com)
1 514 3373333
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): MYG.TO |
| Description: |
MethylGene Inc. (TSX: MYG) is a publicly-traded biotechnology company focused on the clinical development of its proprietary, rationally-designed, small molecule therapeutics. The Company’s lead development product candidates are: MGCD290, an oral fungal Hos2 inhibitor for use in combination with fluconazole for fungal infections, which has commenced Phase 2 clinical studies; and MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met and VEGF receptor tyrosine kinases, currently in multiple clinical trials for cancer. Additional pipeline products include: mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been tested in multiple Phase 2 clinical trials (licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries); MG516, a multi-targeted kinase inhibitor targeting Eph, Ret and Met; MG96077, a novel, broad spectrum, non-beta-lactam beta-lactamase inhibitor designed to overcome beta-lactamase mediated antibiotic resistance; and EVP-0334, a potential cognition enhancing HDAC agent for neurodegenerative diseases that has successfully completed Phase 1 trials sponsored by EnVivo Pharmaceuticals Inc. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.milestonepharma.com |
| Contact: |
Philippe Douville (pdouville@milestonepharma.com)
1 514 4963220
|
| Description: |
Milestone Pharmaceuticals Inc. (“Milestone”) is a cardiovascular drug development company working on novel small molecule therapeutics based on clinically validated mechanisms. Milestone’s approach is to create significant value opportunities without the risk associated with unvalidated therapeutic classes. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.mimetogen.com/ |
| Contact: |
François Mongrain (info@mimetogen.com)
|
| Description: |
Mimetogen Pharmaceuticals is a clinical stage biotechnology company engaged in the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. |
| Location: |
Winnipeg, Manitoba |
| Industry Sector: |
Medical Technology |
| Website: |
www.miraculins.com |
| Contact: |
L. Michael Coutts (info@miraculins.com)
1 204 4531408
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): MOM.V |
| Description: |
Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between commercially available diagnostic tests and research conducted at leading research institutions around the world. |
| Location: |
Winnipeg, Manitoba |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.monsanto.ca |
| Contact: |
Mike McGuire (partnering@monsanto.com)
1 204 9851000
|
| Ownership: |
Subsidiary - New York Stock Exchange (NYSE): MON |
| Description: |
Monsanto Company is a global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. |
| Location: |
Burnaby, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.methylationsciences.com |
| Contact: |
(info@methylationsciences.com)
1 604 4355155
|
| Description: |
Methylation Sciences (“MSI”) is focused on developing pharmaceuticals which are proven to be clinically effective but which have yet to be exploited in major pharmaceutical markets. The first such molecule is s-adenosyl methionine, commonly referred to as “SAMe”. |
